Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akorn, Inc.    AKRX

AKORN, INC. (AKRX)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

AKRX LOSS NOTICE: Rosen Law Firm Reminds Akorn, Inc. Investors of Important Deadline in Class Action

share with twitter share with LinkedIn share with facebook
share via e-mail
0
03/14/2018 | 02:46am CEST

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akorn, Inc. (NASDAQ:AKRX) from March 1, 2017 through February 26, 2018, both dates inclusive (“Class Period”) of the important May 7, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Akorn investors under the federal securities laws.

To join the Akorn class action, go to http://www.rosenlegal.com/cases-1301.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or zhalper@rosenlegal.com for information on the class action.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.

According to the lawsuit, defendants throughout the Class Period made materially false and/or misleading statements and/or failed to disclose that: (1) Akorn’s failure to comply with FDA data integrity requirements would jeopardize Fresenius’s acquisition of Akorn; (2) Akorn lacked effective internal controls over financial reporting; and (3) as a result, Akorn’s financial statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 7, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1301.html to join the class action. You may also contact Phillip Kim or Zachary Halper of Rosen Law Firm toll free at 866-767-3653 or via email at pkim@rosenlegal.com or zhalper@rosenlegal.com.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.


© Business Wire 2018
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AKORN, INC.
08/27Allergan, Mohawk Tribe request rehearing in sovereign immunity IPR case
AQ
08/24TODAY'S RESEARCH REPORTS ON TRENDING : Halozyme Therapeutics and Akorn
AC
08/01AKORN INC : Results of Operations and Financial Condition, Financial Statements ..
AQ
08/01AKORN : Management's Discussion and Analysis of Financial Condition and Results ..
AQ
07/31Complimentary Technical Snapshots on Akorn and Three More Generic Drugs Stock..
AC
07/30TODAY'S RESEARCH REPORTS ON TRENDING : Aurora Cannabis and Akorn
AC
07/13TODAY'S RESEARCH REPORTS ON TRENDING : Akorn and Momenta Pharmaceuticals
AC
07/13Fresenius SE Had Testing Issues Like Akorn's, Executive Says -Bloomberg
DJ
06/25Free Technical Research on Akorn and Three More Generic Drugs Equities
AC
05/29MOORE KUEHN, PLLC : Announces an Investigation Involving Possible Breaches of Fi..
PR
More news
News from SeekingAlpha
09/12Nostrum Labs hikes price of mature antibiotic 400% 
09/07STOCK EXCHANGE : Do You Buy At All Time Highs? 
09/04Merger Arbitrage Mondays - September 3, 2018 
09/02Tracking John Paulson's Paulson & Company Portfolio - Q2 2018 Update 
08/23Akorn down 16% as hearing ends 
Financials ($)
Sales 2018 753 M
EBIT 2018 53,7 M
Net income 2018 -132 M
Debt 2018 526 M
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019 231,13
EV / Sales 2018 2,91x
EV / Sales 2019 2,90x
Capitalization 1 667 M
Chart AKORN, INC.
Duration : Period :
Akorn, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AKORN, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 8
Average target price 27,3 $
Spread / Average Target 105%
EPS Revisions
Managers
NameTitle
Rajat Rai Chief Executive Officer
Alan D. Weinstein Chairman
Bruce Kutinsky Chief Operating Officer
Duane A. Portwood CFO & Executive Vice President
Mark M. Silverberg Executive VP-Operations & Technical Services
Sector and Competitors
1st jan.Capitalization (M$)
AKORN, INC.-57.40%1 667
JOHNSON & JOHNSON-0.16%375 479
PFIZER18.61%252 129
NOVARTIS-0.68%215 800
ROCHE HOLDING LTD.-3.83%212 015
MERCK AND COMPANY25.15%187 284